Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02310230 · ClinicalTrials.gov registry record · NA

An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy

A NA study of Barrett Esophagus and Stomach Neoplasms, sponsored by Donald Mathews.

Completed
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT02310230: Completed NA study of Barrett Esophagus and Stomach Neoplasms, sponsored by Donald Mathews.

NCT02310230 is a NA study of Barrett Esophagus and Stomach Neoplasms that has completed, run by Donald Mathews. The registered enrollment target is 100 participants, below the 3,562-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02310230, a NA study of Barrett Esophagus and Stomach Neoplasms, has completed, sponsored by Donald Mathews.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Purpose: To assess the utility of a new medical device that monitors a patient's breathing during medical procedures in which a patient is sedated, but not mechanically ventilated. In minor procedures, such as endoscopy (where the doctor examines a patient's digestive tract by a TV camera inserted through the mouth), patients do not require general anesthesia, in which a machine would take over their breathing while they are unconscious for surgery. However, during endoscopic procedures it is sometimes difficult for the anesthesiologist to monitor the patient's breathing-specifically, to monitor changes in breathing patterns and the adequacy of breathing. In endoscopy procedures, the room is darkened, and the patient's mouth is generally occupied by the endoscope. While the anesthesiologist can listen to the patient's breathing sounds with a stethoscope, this type of monitoring can only be done periodically, and there is limited ability to gauge the adequacy of ventilation. This study will use the ExSpiron Respiratory Volume Monitor (RVM), which measures non-invasive minute ventilation (MV), tidal volume (TV) and respiratory rate (RR), in patients undergoing an endoscopic procedure to provide additional information regarding the effects of clinical interventions such as drug administrations or airway maneuvers on the patient's respiratory status. For patients who give informed consent, study participation means that they will have a PadSet consisting of 3 electrodes applied to the chest. Another component, a nasal cannula (a thin clear plastic tube that goes under the nose) will give patients supplemental oxygen, and is standard of care for endoscopy at UVM Medical Center. Patients will then be asked to breathe in and out of a portable spirometer (breath meter) for 30 seconds up to five times. This data will be compared to data recorded by the monitor to confirm that the monitor is recording accurately. The procedure will then go forward in the normal fashion. Pati

Primary Outcome

Minute ventilation (or respiratory minute volume) is defined as the volume of air that can be inhaled or exhaled during one minute. The ExSpiron Respiratory Variation Monitor is able to quantify respiratory rate and also determine tidal volume and minute ventilation. The monitor measures a patient's baseline minute ventilation (MV) at the beginning of the case, and then compares subsequent minute volumes to that baseline, measured as a percentage of the baseline. In that respect, the minute vent

Interventions

  • DEVICE ExSpiron Respiratory Variation Monitor

Study Locations (1)

Vermont

  • University of Vermont Medical Center - Burlington

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2014-09-22
Est. Completion 2016-05-09
Phase NA
Donald Mathews

2 total trials

What the finished NCT02310230 record still lists

NCT02310230 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 3,562-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (97% lower).

The record links to 4 conditions, with Barrett Esophagus appearing as the primary indexed condition, and to 1 intervention - of which ExSpiron Respiratory Variation Monitor is the first listed.

NCT02310230 reports a single indexed study location in Vermont.

Frequently Asked Questions

What is clinical trial NCT02310230 about?

NCT02310230 is a clinical study titled "An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy". Purpose: To assess the utility of a new medical device that monitors a patient's breathing during medical procedures in which a patient is sedated, but not mechanically ventilated. In minor procedures, such as endoscopy (where the doctor examines a patient's digestive tract by a TV camera inserted t...

What is the current status of trial NCT02310230?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2014-09-22. Estimated completion is 2016-05-09.

What conditions does trial NCT02310230 study?

This clinical trial studies the following conditions: Barrett Esophagus, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Biliary Tract Diseases.

What interventions are being tested in trial NCT02310230?

The interventions under investigation include: ExSpiron Respiratory Variation Monitor (DEVICE).

Who is sponsoring clinical trial NCT02310230?

This trial is sponsored by Donald Mathews, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02310230 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02310230's enrollment target sits among peer trials

100 21st of 32 higher than 11 of 32 other Barrett Esophagus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Barrett Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02310230, the US trial registry maintained by the National Library of Medicine. NCT02310230 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.